Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations at the 35th Annual American Academy of Pain Medicine Meeting
March 07, 2019 07:30 ET
|
Centrexion Therapeutics
Company will present two posters on CNTX-4975 for treatment of moderate to severe knee osteoarthritis pain;pharmacological data from preclinical and Phase 1 and 2 clinical trials describing the...
Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 Clinical Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
December 05, 2018 07:30 ET
|
Centrexion Therapeutics
BOSTON, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today...